Answer
Breastfeeding should be discontinued during entrectinib (Rozlytrek) treatment because it is unknown whether entrectinib or its metabolites enter human milk, and a risk to breastfed children cannot be excluded.
Sources for this answer
- Rozlytrek 100 mg & 200 mg hard capsulesRoche Products Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 16Document updated
Sources checked